HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TVRD
Tvardi Therapeutics, Inc.
There isn't enough reported data to score TVRD yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TVRD Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Unavailable | |
| Strong |
TVRD's balance sheet is currently strong, but its revenue and profitability are under pressure. There isn't enough data to rate its cash flow.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TVRD PE Valuation
TVRD has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TVRD Forward outlook
There aren't enough analyst estimates for TVRD to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
TVRD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.79 | +$14.54 |
| Q1 2026 | -$3.10 | +$26.55 |
| Q4 2025 | -$5.59 | +$41.00 |
| Q3 2025 | -$9.64 | +$53.72 |
| Q2 2025 | -$17.33 | +$56.47 |
| Q1 2025 | -$29.65 | +$51.71 |
| Q4 2024 | -$46.59 | +$32.25 |
| Q3 2024 | -$63.36 | +$14.04 |
TVRD has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the stronger quarterly revenue trend. Revenue is up 49% for HIMS versus up 20% for TVRD.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
TVRD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2025 | $2.6M | +20% |
| Q4 2024 | $1.5M | -52% |
| Q3 2024 | $2.6M | -47% |
| Q2 2024 | $991K | -86% |
| Q1 2024 | $2.1M | -65% |
| Q4 2023 | $3M | -7.9% |
| Q3 2023 | $4.9M | -55% |
| Q2 2023 | $6.9M | -70% |
TVRD's revenue is recovering but still below its 2020 peak: $3M last quarter, up 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -93% | +1297 points |
| Q4 2024 | -373% | +713 points |
| Q3 2024 | -234% | +360 points |
| Q2 2024 | -1746% | -1280 points |
| Q1 2024 | -1390% | -941 points |
| Q4 2023 | -1085% | -125 points |
| Q3 2023 | -594% | -373 points |
| Q2 2023 | -466% | -447 points |
TVRD's operating margin was −93% last quarter, up 1297 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
TVRD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$9.2M | -$363K |
| Q4 2025 | -$5.7M | -$1.6M |
| Q3 2025 | -$4.3M | +$9.7M |
| Q2 2025 | -$8.9M | +$3.8M |
| Q4 2024 | -$4M | +$15.4M |
| Q4 2023 | -$19.4M | +$4.1M |
| Q2 2022 | -$4.5M | +$16.5M |
| Q1 2022 | -$25.6M | -$1.8M |
TVRD has burned cash in almost every quarter: −$25M over the past year, against −$40M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TVRD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TVRD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +11% | +926K shares |
| 3 years | +525% | +7.9M shares |
| 5 years | +575% | +8M shares |
| Available history | +659% | +8.1M shares |
TVRD has 9M diluted shares, up 11% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TVRD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2021 | -1.0x | Net Cash |
| Q2 2021 | -3.2x | Net Cash |
| Q1 2021 | -1.9x | Net Cash |
| Q4 2020 | -5.7x | Net Cash |
TVRD has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TVRD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.5 | Neutral |
| Stochastic | 15.1 | Oversold |
TVRD's weekly RSI is 36 (neutral) and its Stochastic is 15 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TVRD PE vs Healthcare Sector
TVRD has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
TVRD has stronger trend alignment. HIMS is above 0 of 5 weekly averages versus TVRD above 1 of 3.
TVRD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.04 | 12% above |
| 20 week MA | $1.71 | 32% below |
| 50 week MA | $2.86 | 59% below |
TVRD has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 59% below its 50-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over TVRD on returns for 2026, with the stronger performance.
TVRD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $14.7 | $4.14 | -72% |
| 2026 YTD | $4.14 | $1.16 | -72% |
TVRD has finished every year since 2025 lower, and it's down 72% so far in 2026.